Replies to post #251107 on Avid Bioservices Inc (CDMO)

[tradero]

Sorry EX, I dont exactly know the method used by Golfho, I used my own eventing system (probably similar to his, but I dont really know).
I just based my enrollment method on his.
When I have some time I will take a deeper look at it, but I guess he is the one who would know better.

And yeah, I agree with you that these simulations and reality may be far apart.

Too many assumptions that can be wrong... And depending on how wrong they are our calculations will be close enough or not.
But I dont think anyone will bet his farm on this... It is just a guessing game, something to play with while we wait...

[Protector]

exwannabe, not sure if all that matters since the only think we want to hear is CONTINUE and what we do NOT want to hear is STOP FUTILITY.

P.S: This estimation game is fun, but often ends up not being very accurate for many reasons. Will the curves have late separation (which is good, but not show up much this early). Could PD-L1 expression testing results effect trial selection (and who knows what that would actually mean). ...

Of course also safety but I don't think that there is any bavituximab follower that that doubts about safety after a 100% safety track-record on 750 patients in total now.

We have been told the IDMC would only look for what was requested by the protocol for the 1st look-in and PPHM Shan and CEO King both told us 1st look-in is for safety and futility, not efficacy.